The use of ROX index to predict failure of high-flow nasal cannula in patients with COVID-19 associated acute respiratory distress syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20230206002

Enrollment

212

Registered

2023-02-06

Start date

2021-07-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with mild- to moderate COVID-19-associated acute respiratory distress syndrome (ARDS) can be treated with high-flow nasal cannula (HFNC). COVID-19 associated acute respiratory distress syndrome high-flow nasal cannula HFNC failure ROX index prediction

Interventions

Those patients with subsequent endotracheal tube intubation were required.

Diagnostic

HFNC failure

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 or older. 2. Patients with confirmed diagnosis of COVID-19 infection using a positive for reverse transcription polymerase chain reaction (RT-PCR) 3. Bilateral infiltration in chest radiography 4. Started HFNC therapy during hospitalization.

Exclusion criteria

Exclusion criteria: 1. Patients who initiated IMV before commencing HFNC therapy. 2. Patients with signed a do-not-resuscitate advance medical directive. 3. Patients who transferred to another hospital during HFNC therapy.

Design outcomes

Primary

Measure	Time frame
HFNC failure During HFNC therapy Yes/No	—

Secondary

Measure	Time frame
n/a n/a n/a	—

Countries

Thailand

Contacts

Public ContactSujaree Poopipatpab

Faculty of Medicine Vajira Hospital, Navamindradhiraj University

aungaey@gmail.com0818011547

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026